<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400150</url>
  </required_header>
  <id_info>
    <org_study_id>BP-007</org_study_id>
    <nct_id>NCT03400150</nct_id>
  </id_info>
  <brief_title>ProSpace™ Balloon System Pivotal Study BP-007</brief_title>
  <official_title>CLINICAL PROTOCOL for the INVESTIGATION Of the ProSpace™ Balloon System Pivotal Study BP-007</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioProtect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioProtect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ProSpace™ System is intended to temporarily position the anterior rectal wall away from
      the prostate during radiotherapy for prostate cancer and in creating this space it is the
      intent of the ProSpace System to reduce the radiation dose delivered to the anterior rectum.
      ProSpace is a balloon composed of a biodegradable material that maintains that space for the
      entire course of prostate radiotherapy treatment and is completely absorbed by the patient's
      body over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a prospective, multi-center, randomized, double-arm, single blind,
      concurrently controlled study to assess the safety and efficacy of the ProSpace Balloon in
      prostate cancer subjects undergoing radiotherapy by means of intensity modulation radiation
      therapy (IMRT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized in a 2:1 ratio (ProSpace implantation:control)</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Study subjects are blinded to group assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Rate of Occurrence</measure>
    <time_frame>Duration of at least 2 days through 6 months</time_frame>
    <description>Rate of occurrence of Grade 1 or greater rectal adverse events and implantation procedure related adverse events through 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in Rectal Radiation Exposure</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of at least 25% of the volume of the rectum receiving greater or equal to 70 Gy (VRectum70) when compared to pre-implantation values.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">222</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ProSpace group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT + marking + ProSpace implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>IMRT + marking</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ProSpace</intervention_name>
    <description>ProSpace balloon implantation</description>
    <arm_group_label>ProSpace group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Control - no study intervention</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age

          -  Have been histologically diagnosed with invasive adenocarcinoma of the prostate, at
             clinical stage T1-T3 (as determined by a biopsy taken within 6 months of the screening
             visit)

          -  Be scheduled for radiation therapy (XRT) by means of IMRT

        Exclusion Criteria:

          -  Any prior invasive malignancy (except non-melanomatous skin cancer) unless the subject
             has been disease free for a minimum of 5 years

          -  Prior radical prostatectomy

          -  Prior cryosurgery or radiotherapy for prostate cancer, or other local therapy for
             prostate cancer

          -  Prior radiotherapy to the pelvis, including brachytherapy

          -  History of prior surgery involving the rectum or anus

          -  Prior surgical procedure involving the peri-rectal and/or peri-prostatic area
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joyce Dunsmore</last_name>
    <phone>703-628-8603</phone>
    <email>joyce@bioprotect.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Urology Nevada</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89521</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CUF</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Portugal</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bioprotect.co.il/</url>
    <description>Company website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2018</study_first_submitted>
  <study_first_submitted_qc>January 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

